Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Other Non-Current Liabilities (2021 - 2025)

Coeptis Therapeutics Holdings has reported Other Non-Current Liabilities over the past 5 years, most recently at $167625.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $167625.0 for Q4 2025, down 53.34% from a year ago — trailing twelve months through Dec 2025 was $167625.0 (down 53.34% YoY), and the annual figure for FY2025 was $167625.0, down 53.34%.
  • Other Non-Current Liabilities for Q4 2025 was $167625.0 at Coeptis Therapeutics Holdings, down from $409500.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for COEPW hit a ceiling of $8.1 million in Q2 2021 and a floor of $88125.0 in Q1 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $467250.0 (2025), compared with a mean of $1.5 million.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 92.63% in 2022 and later soared 143.75% in 2023.
  • Coeptis Therapeutics Holdings' Other Non-Current Liabilities stood at $3.9 million in 2021, then tumbled by 70.87% to $1.1 million in 2022, then crashed by 50.47% to $557250.0 in 2023, then crashed by 35.53% to $359250.0 in 2024, then plummeted by 53.34% to $167625.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $167625.0 (Q4 2025), $409500.0 (Q3 2025), and $467250.0 (Q2 2025) per Business Quant data.